Title: Somapacitan-Beco: For Adult Human Growth Hormone Deficiency
Author: Harichandana Punukula
DOI: https://dx.doi.org/10.18535/jmscr/v8i9.45
Abstract
Somapacitan (Sogroya) is the first human hormone of growth (hGH) therapy that is only administered once a week by injection under the skin; other FDA-approved hGH formulations must be given daily to adults with growth hormone deficiency. Somapacitan in adults with a growth hormone deficit (GHD) is suggested for the replacement of endogenous growth hormone.
GHD is a disorder in which the body contains not enough growth hormone alone. Growth hormone controls many functions in the body, including fat storage in the trunk or central region of the body, and is related to severe medical conditions. Here we are presenting side effects, limitations and the therapeutic efficacy of somapacitan in accomplishing the human growth harmone deficiency.
Keywords: Somapacitan, human growth factor, Sogroya.
References
- FDA approves weekly therapy for adult growth hormone deficiency. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-weekly-therapy-adult-growth-hormone-deficiency. Accessed September 2, 2020.
- FDA approves once-weekly Sogroya® for the treatment of adult growth hormone deficiency. https://www.novonordisk-us.com/media/news-releases.html?122995. Accessed September 2, 2020.
- Sogroya [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2020.
- Kargi A, Merriam G. Diagnosis and treatment of growth hormone deficiency in adults. Nat Rev Endocronol. 2013;(9):335-345.
- Brod M, Pohlman B, Hojbjerre L, Adalsteinsson JE, Rasmussen MH. Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Research Notes. 2014;7(813):1-9.